Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection.
Following primary ocular infection, HSV-1 establishes a latent infection in the trigeminal ganglia with the complete absence of detectable infectious virus. Recently, we showed that vaccination of BALB/cJ with HSV-1 glycoprotein K (gK), but not other HSV-1 glycoproteins, significantly exacerbated the severity of HSV-1-induced ocular disease and herpetic dermatitis (H. Ghiasi et al. J. Virol. 68, 2347-2354, 1994). We now report that prior vaccination with gK blocked viral clearance from trigeminal ganglia until at least Day 56 postinfection, resulting in a chronic infection. The significance of this novel finding with respect to potential harmful complications associated with the immune response to gK is discussed.
Ghiasi
H
H
Cedars-Sinai Medical Research Institute, Los Angeles, California 90048, USA.
Cai
S
S
Nesburn
A B
AB
Wechsler
S L
SL
D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D005123:Eye / Q000821:virology; D006561:Herpes Simplex / Q000276:immunology* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000276:immunology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D012668:Trigeminal Ganglion / Q000821:virology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017735:Virus Latency
C072448:UL53 protein, Human herpesvirus 1; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines